Short Interest in Inhibitor Therapeutics, Inc. (OTCMKTS:INTI) Decreases By 60.6%

Inhibitor Therapeutics, Inc. (OTCMKTS:INTI) saw a large decline in short interest in June. As of June 30th, there was short interest totaling 4,645 shares, a decline of 60.6% from the June 15th total of 11,804 shares. Approximately 0.0% of the shares of the stock are sold short. Based on an average daily trading volume, of 6,542 shares, the days-to-cover ratio is presently 0.7 days.

Inhibitor Therapeutics Stock Performance

Shares of Inhibitor Therapeutics stock opened at $0.08 on Monday. The company has a 50 day moving average of $0.08 and a 200-day moving average of $0.08. Inhibitor Therapeutics has a 1-year low of $0.04 and a 1-year high of $0.12. The company has a market cap of $13.64 million, a PE ratio of -7.85 and a beta of -0.78.

About Inhibitor Therapeutics

Inhibitor Therapeutics, Inc, a pharmaceutical development company, develops and commercializes therapeutics for patients with certain cancers and non-cancerous proliferation disorders in the United States. The company engages in the development of therapies for prostate and lung cancer utilizing itraconazole; and conducted a positive Phase 2b clinical trial of SUBA-Itraconazole for the treatment of basal cell carcinoma nevus syndrome. It has license agreement with Johns Hopkins University. The company was formerly known as HedgePath Pharmaceuticals, Inc and changed its name to Inhibitor Therapeutics, Inc in August 2019.